<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">Specifically, when dealing with the detection and diagnosis of COVID-19, the tests are based on specific nucleic acids and proteins, as well as point-of-care testing [
 <xref ref-type="bibr" rid="CR104">104</xref>]. Protein-based tests (serology) are a standard, widely accepted method as the first choice in large-scale tests for the detection of viruses in the body and are based on the presence of specific viral antigens or corresponding antibody responses of the immune system. However, the accuracy, reliability, and selectivity of these tests are commonly confronted by the possibility of cross-reactivity of the antibodies used, which can increase the risk of false positives [
 <xref ref-type="bibr" rid="CR103">103</xref>]. Another important limitation occurs in the diagnosis of individuals with a viral load in its initial representation or when a mutation occurs during the propagation period [
 <xref ref-type="bibr" rid="CR109">109</xref>].
</p>
